

Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX.V: TRX)

151 Steeles Avenue East
Milton, ON L9T 1Y1

Share Price (OTCQX)	\$0.93
Volume	0
Shares Outstanding	113,719,683
Market Cap	\$105.76m
52 Week High	\$1.86
52 Week Low	\$0.50

as of 02/24/2016



Overview

Tribute Pharmaceuticals Canada Inc. ("Tribute") is a leading Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US. The Company targets several therapeutic areas but has a particular interest in products for the treatment of pain, neurology, dermatology, cardiology, endocrinology and specialty care. Tribute also sells Uracyst® and NeoVisc® internationally through a number of strategic partnerships. Tribute currently markets NeoVisc® Single Dose, NeoVisc® Triple Dose, Uracyst®, Soriatane®, Bezalip® SR, Cambia®, Fiorinal®, Fiorinal® C, Visken® and Viskazide in Canada and has the US rights to Bezalip® SR and global rights to Uracyst® and NeoVisc®. Additionally, Tribute has the exclusive Canadian rights to bilastine in Canada (not yet approved).

Management Team

Robert (Rob) Harris

Director, President & Chief Executive Officer

Scott Langille

Director & Chief Financial Officer

Dr. Bernard Chiasson

Chief Scientific Officer

Janice M. Clarke

VP of Finance & Administration

Murray Roach

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

VP of Sales and Marketing

David Butts

VP of Commercial Operations

Paul MacPherson

VP Manufacturing & Operations

Recent News

Monday, February 01, 2016 - 11:04 AM

[Tribute Announces Results of Shareholder Vote](#)

Thursday, January 21, 2016 - 07:30 AM

[Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction](#)

Monday, January 11, 2016 - 07:30 AM

[Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote](#)

Monday, January 04, 2016 - 07:30 AM

[Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia\(R\) Use in Migraine Treatment](#)

Tuesday, December 29, 2015 - 08:00 AM

[RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016](#)